Jeroen B. Van Beek - Aug 16, 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role
Chief Commercial Officer
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Stock symbol
ALVR
Transactions as of
Aug 16, 2022
Transactions value $
-$129,473
Form type
4
Date filed
8/17/2022, 05:58 PM
Previous filing
Jul 21, 2022
Next filing
Sep 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Sale -$129K -15.6K -3.88% $8.30 386K Aug 16, 2022 Direct F1, F2
transaction ALVR Common Stock Award $0 +15K +3.88% $0.00 401K Aug 16, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), and does not represent a discretionary trade by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.12 to $8.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The shares reported in this transaction represent RSUs issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.